VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations
about
Nebulization as a delivery method for mAbs in respiratory diseases.VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
P2860
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@ast
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@en
type
label
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@ast
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@en
prefLabel
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@ast
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@en
P2093
P2860
P356
P1476
VEGF neutralizing aerosol ther ...... ith K-ras activating-mutations
@en
P2093
Delphine Fouquenet
Etienne Lemarié
Flora Paul
Françoise Redini
Gilles Paintaud
Jacques Cadranel
Jérôme Montharu
Laurent Guilleminault
Laurène Schlick
Marie Wislez
P2860
P304
P356
10.4161/MABS.34454
P577
2014-01-01T00:00:00Z